InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,745.37
(
0.40%
)
US TECH 100
19,572.80
(
0.72%
)
Dow Jones
42,175.11
(
0.62%
)
Brent Oil
70.86
(
-3.19%
)
Bitcoin
64,737.66
(
2.54%
)
Post# of 43374
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Fezziwig2008

Send PM Follow Ignore
Followers 24
Posts 501
Boards Moderated 1
Alias Born 03/09/2014

Fezziwig2008

Re: None

Monday, 10/19/2020 7:06:05 AM

Monday, October 19, 2020 7:06:05 AM

Post# of 43374
HGEN - $GILD has a problem in severe COVID - “ WHO Director General Tedros Adhanom Ghebreyesus defended the so-called Solidarity Trial, which was launched to study the effectiveness of remdesivir and three other drugs in treating COVID-19, as the largest trial in the world. It included more than 11,000 coronavirus patients across 30 countries, with more than 2,700 participants given remdesivir.” No Benefit.

https://www.google.com/amp/s/www.usnews.com/news/health-news/articles/2020-10-16/who-addresses-gileads-pushback-on-remdesivir-trial%3fcontext=amp

AND they have access to UNblinded HGEN - Lenzilumab-Yescarta data - Cytokine storm In CAR-T is Cytokine storm in COVID- O’Day can treat two storms with one deal.

https://clinicaltrials.gov/ct2/show/NCT04314843?term=Lenzilumab&draw=2&rank=2
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up